EL7.AI
StocksUpdated•Originally published 15 April 2026•Updated 16 April 2026•
1 min read

Niagen Bioscience Pivots to Telehealth Model to Drive Higher Margins

Key Facts

1Niagen Bioscience is transitioning from supplements to a telehealth-driven longevity platform.
2The company targets higher margins and valuations through the launch of Niagen Plus injectables.
3Analysts project a 40% to 75% upside as the recurring revenue model matures.

Niagen Bioscience is advancing its strategic pivot toward a telehealth-driven longevity platform, aiming for higher margins and valuations consistent with HealthTech standards. This transition is supported by a robust balance sheet featuring low debt levels and high cash reserves, providing essential financial flexibility during market distress. However, the company faces macroeconomic headwinds such as low consumer confidence and high energy prices, alongside the internal risk of shareholder dilution from potential new share issuances. Despite these risks, projections for revenue growth and profitability improvements in fiscal 2025 are positioning the stock as an attractive option for growth-focused investors. The launch of Niagen Plus injectables remains central to capturing recurring revenue and leveraging the firm's intellectual property moat. Ultimately, the move is designed to drive long-term shareholder value by transitioning away from low-margin retail models.